+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Fitness of Biocompatible High-Flux Hemodiafiltration for Dialysis-Related Amyloidosis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Aims: In order to assess the long-term influence of high-flux hemodiafiltration (HDF) on hemodynamic stability in patients with dialysis-related amyloidosis. Methods: HDF with high-flux dialyzers was performed for a year in 11 patients who had undergone the surgery for carpal tunnel syndrome. Patients were divided into two groups, and for each group synthetic or cellulose membrane dialyzers were applied. Results: A year after the exchange from standard hemodialysis to HDF with cellulose high-flux dialyzers, β<sub>2</sub>-microglobulin was decreased (45 ± 3 to 28 ± 2 mg/l, n = 5, p < 0.05), but plasma non-refilling ratio was not altered. However, the continuance of synthetic high-flux HDF for a year decreased plasma non-refilling ratio (17 ± 5 to 7 ± 4%, p < 0.05), hypotensive episodes (4.3 ± 0.6 to 2.5 ± 0.4 sessions/month, p < 0.05) and muscle cramps (3.8 ± 0.5 to 1.8 ± 0.5 sessions/month, p < 0.01) in addition to the decrements in serum β<sub>2</sub>-microglobulin (45 ± 5 to 33 ± 2 mg/l, n = 6, p < 0.01). Conclusions: Although the study on a large number of patients may be required to draw a final conclusion, our present data suggest that biocompatible high-flux HDF is uniquely suited for dialysis-related amyloidosis.

          Related collections

          Author and article information

          Blood Purif
          Blood Purification
          S. Karger AG
          08 December 2000
          : 19
          : 1
          : 10-14
          aShinjuku Suimei Clinic, Shinjuku; bTsuchiya Clinic, Koto; cKokubunji Minamiguchi Clinic, Kokubunji, Tokyo, and dDepartment of Medicine, Saitama Medical College, Iruma, Saitama, Japan
          14471 Blood Purif 2001;19:10–14
          © 2001 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 2, Tables: 1, References: 20, Pages: 5
          Self URI (application/pdf):
          Original Paper


          Comment on this article